Next Article in Journal
Gene Expression and Protein Abundance of Hepatic Drug Metabolizing Enzymes in Liver Pathology
Next Article in Special Issue
Poly(lactic-co-glycolic acid) Nanoparticles Encapsulating the Prenylated Flavonoid, Xanthohumol, Protect Corneal Epithelial Cells from Dry Eye Disease-Associated Oxidative Stress
Previous Article in Journal
In Vitro Interaction and Killing-Kinetics of Amphotericin B Combined with Anidulafungin or Caspofungin against Candida auris
Previous Article in Special Issue
Effect of Carbon Chain Length, Ionic Strength, and pH on the In Vitro Release Kinetics of Cationic Drugs from Fatty-Acid-Loaded Contact Lenses
Article

A Long-Acting Curcumin Nanoparticle/In Situ Hydrogel Composite for the Treatment of Uveal Melanoma

1
Department of Biomedical and Pharmaceutical Sciences, University of Rhode Island, Kingston, RI 02881, USA
2
Department of Chemical Engineering, University of Rhode Island, Kingston, RI 02881, USA
*
Author to whom correspondence should be addressed.
Academic Editors: Anuj Chauhan, Laurence Fitzhenry, Ana Paula Serro and Monica M. Jablonski
Pharmaceutics 2021, 13(9), 1335; https://doi.org/10.3390/pharmaceutics13091335
Received: 23 June 2021 / Revised: 8 August 2021 / Accepted: 22 August 2021 / Published: 25 August 2021
(This article belongs to the Special Issue Recent Advances in Ophthalmic Drug Delivery)
Uveal melanoma (UM) is the most common primary intraocular tumor in adults with high mortality. In order to improve prognosis and survival of UM patients, it is critical to inhibit tumor progression and metastasis as early as possible after the initial presentation/diagnosis of the disease. Sustained local delivery of antitumor therapeutics in the posterior region can potentially achieve long-term UM inhibition, improve target therapeutic delivery to the posterior segments, as well as reduce injection frequency and hence improved patient compliance. To address the highly unmet medical need in UM therapy, a bioinspired in situ gelling hydrogel system composed of naturally occurring biopolymers collagen and hyaluronic acid was developed in the present research. Curcumin with anti-cancer progression, anti-metastasis effects, and good ocular safety was chosen as the model therapeutic. The developed in situ gelling delivery system gelled at 37 °C within two minutes and demonstrated excellent biocompatibility and slow degradation. The curcumin-loaded nanoparticle/hydrogel composite was able to sustain release payload for up to four weeks. The optimized nanoparticle/hydrogel composite showed effective inhibition of human UM cell proliferation. This novel nanoparticle/in situ hydrogel composite demonstrated a great potential for the treatment of the rare and devastating intraocular cancer. View Full-Text
Keywords: in situ hydrogel; nanoparticle/hydrogel composite; sustained delivery; curcumin; uveal melanoma in situ hydrogel; nanoparticle/hydrogel composite; sustained delivery; curcumin; uveal melanoma
Show Figures

Figure 1

MDPI and ACS Style

Xie, L.; Yue, W.; Ibrahim, K.; Shen, J. A Long-Acting Curcumin Nanoparticle/In Situ Hydrogel Composite for the Treatment of Uveal Melanoma. Pharmaceutics 2021, 13, 1335. https://doi.org/10.3390/pharmaceutics13091335

AMA Style

Xie L, Yue W, Ibrahim K, Shen J. A Long-Acting Curcumin Nanoparticle/In Situ Hydrogel Composite for the Treatment of Uveal Melanoma. Pharmaceutics. 2021; 13(9):1335. https://doi.org/10.3390/pharmaceutics13091335

Chicago/Turabian Style

Xie, Lingxiao, Weizhou Yue, Khaled Ibrahim, and Jie Shen. 2021. "A Long-Acting Curcumin Nanoparticle/In Situ Hydrogel Composite for the Treatment of Uveal Melanoma" Pharmaceutics 13, no. 9: 1335. https://doi.org/10.3390/pharmaceutics13091335

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop